Description
CJC-1295 and Ipamorelin are research peptides studied for their activity within the growth hormone–releasing hormone and growth hormone secretagogue signaling pathways. CJC-1295 is an analogue of growth hormone–releasing hormone, commonly abbreviated as GHRH. It is researched for its potential interaction with GHRH receptors and its influence on pulsatile growth hormone signaling.
Ipamorelin is a selective growth hormone secretagogue and ghrelin-receptor agonist. It is studied for its potential ability to activate growth hormone secretagogue receptor pathways. Researchers may evaluate CJC-1295 and Ipamorelin together because they act through separate but potentially complementary signaling mechanisms.
Laboratory and clinical research has examined these peptides in connection with:
- Growth hormone–releasing hormone receptor activity
- Growth hormone secretagogue receptor signaling
- Pulsatile growth hormone release
- Growth hormone and IGF-1-related pathways
- Pituitary and hypothalamic signaling
- Protein synthesis and muscle-metabolism pathways
- Lipid metabolism and body-composition mechanisms
- Exercise-response and recovery-related pathways
- Collagen and connective-tissue metabolism
- Bone-remodeling and bone-density pathways
- Sleep-associated growth hormone secretion
- Age-associated changes in the growth hormone axis
- Glucose and insulin-related metabolic signaling
- Pharmacokinetic differences between GHRH analogues and secretagogues
